MAVERIX ONCOLOGY INC has a total of 19 patent applications. Its first patent ever was published in 2019. It filed its patents most often in Australia, Brazil and Canada. Its main competitors in its focus markets pharmaceuticals, measurement and organic fine chemistry are JIANGXI INST FOR DRUG CONTROL, ZIEGLER RANDY H and FUNDACIO INST DE RECERCA DE LHOSPITAL DE LA SANTA CREU I SANT PAU.
# | Country | Total Patents | |
---|---|---|---|
#1 | Australia | 2 | |
#2 | Brazil | 2 | |
#3 | Canada | 2 | |
#4 | China | 2 | |
#5 | EPO (European Patent Office) | 2 | |
#6 | Israel | 2 | |
#7 | Republic of Korea | 2 | |
#8 | Chile | 1 | |
#9 | Colombia | 1 | |
#10 | Peru | 1 | |
#11 | Singapore | 1 | |
#12 | United States | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Measurement | |
#3 | Organic fine chemistry |
# | Technology | |
---|---|---|
#1 | Analysing materials | |
#2 | Sugars | |
#3 | Therapeutic chemical compounds | |
#4 | Medical preparations |
# | Name | Total Patents |
---|---|---|
#1 | Coburn Craig Alan | 15 |
#2 | Everett Steven Albert | 14 |
#3 | Craig Alan Coburn | 2 |
#4 | Steven Albert Everett | 2 |
#5 | Verett Steven Albert | 1 |
Publication | Filing date | Title |
---|---|---|
CN112135634A | Small molecule drug conjugate of gemcitabine monophosphate | |
CN112135635A | Novel small molecule drug conjugate of gemcitabine derivative |